Matthias Simon
A5027219967- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Bioinformatics and Genomic Networks
- Ferroptosis and cancer prognosis
- Computational Drug Discovery Methods
- Chromatin Remodeling and Cancer
- Mathematical Biology Tumor Growth
- Neurofibromatosis and Schwannoma Cases
- Vascular Malformations Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cell Image Analysis Techniques
- Metabolomics and Mass Spectrometry Studies
- RNA modifications and cancer
- Head and Neck Surgical Oncology
- Microtubule and mitosis dynamics
- Cerebrospinal fluid and hydrocephalus
- Epilepsy research and treatment
- Hedgehog Signaling Pathway Studies
- Drug Transport and Resistance Mechanisms
Evangelisches Krankenhaus Bielefeld
2017-2024
University Hospital Bonn
2014-2024
Bielefeld University
2021-2024
Bethel University
2023-2024
Heinrich Heine University Düsseldorf
2007-2023
University of Bonn
2013-2023
Düsseldorf University Hospital
2007-2023
Forschungsverbund Berlin
2021-2022
Foundation University Islamabad
2021
Philips (Netherlands)
2020
The prognostic value of genetic alterations characteristic glioblastoma in patients treated according to present standards care is unclear.Three hundred one with were prospectively recruited between October 2004 and December 2006 at the clinical centers German Glioma Network. Two fifty-eight had radiotherapy, 199 temozolomide, 189 both, seven another chemotherapy as initial treatment. tumors investigated for TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor,...
Purpose Invasion and migration are key processes of glioblastoma tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy radiotherapy in vitro promising activity recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy safety combination standard chemoradiotherapy newly diagnosed Patients Methods (age ≥ 18 ≤ 70 years) were treated (500 mg) administered twice weekly intravenously addition concomitant adjuvant...
Journal Article 'Go or Grow': the key to emergence of invasion in tumour progression? Get access H. Hatzikirou, Hatzikirou * School Health Information Sciences, University Texas Science Center at Houston, 7000 Fannin, TX 77030, USA *Corresponding author: haralampos.hatzikirou@uth.tmc.edu Search for other works by this author on: Oxford Academic Google Scholar D. Basanta, Basanta Integrated Mathematical Oncology, H.Lee Moffitt Cancer and Research Institute, 12902 Magnolia Drive Tampa, FL...
The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because high interobserver variation some criteria, more reliable prognostic markers are required. Here, we assessed TERT promoter for mutations in hotspot regions C228T C250T meningioma samples from 252 patients. Mutations were detected 16 (6.4% across cohort, 1.7%, 5.7%, 20.0% WHO grade I, II, III cases, respectively). Data...
O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation identifies a subpopulation of glioblastoma patients with more favorable prognosis and predicts benefit from alkylating agent chemotherapy (CT). Little is known about its prevalence clinical significance in older patients. We studied 233 aged 70 years or (144 males, 89 females, median age: 74 years, range: 70.0-86.6 years), who were prospectively enrolled the German Glioma Network, for MGMT by methylation-specific PCR (MSP)...
While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens tumor recurrence remain mostly individualized. The role a surgical resection recurrent remains largely unclear at present. This study aimed to assess effect repeated on patient survival. In multicenter retrospective-design study, patients with primary undergoing repeat resections tumors were evaluated factors affecting Age, Karnofsky performance status (KPS), extent (EOR), location, and...
<h3>Objective:</h3> To explore whether the isocitrate dehydrogenase 1 (<i>IDH1</i>) or 1p/19q status determines prognostic vs predictive role of O<sup>6</sup>-methylguanine-DNA methyltransferase (<i>MGMT</i>) promoter methylation in Neuro-Oncology Working Group German Cancer Society (NOA)-04 trial anaplastic glioma biomarker cohort. <h3>Methods:</h3> Patients (n = 183) NOA-04 with known <i>MGMT</i> and <i>IDH1</i> were analyzed for interdependency from treatment, using progression-free...
BackgroundActivating somatic mutations in the promoter region of telomerase reverse transcriptase gene (TERT) have been detected several cancers. In this study we investigated TERT and their impact on patient survival World Health Organization grade IV glioblastoma multiforme (GBM).
OBJECTIVE Recent advances in radiotherapy and neuroimaging have called into question the traditional role of aggressive resections patients with meningiomas. In present study authors reviewed their institutional experience a policy based on maximal safe for meningiomas, they analyzed impact degree resection functional outcome progression-free survival (PFS). METHODS The retrospectively 901 consecutive primary meningiomas (716 WHO Grade I, 174 II, 11 III) who underwent at University Hospital...
Abstract Meningiomas are mostly benign brain tumours, with a potential for becoming atypical or malignant. On the basis of comprehensive genomic, transcriptomic and epigenomic analyses, we compared meningiomas to ones. Here, show that majority primary ( de novo ) display loss NF2 , which co-occurs either genomic instability recurrent SMARCB1 mutations. These tumours harbour increased H3K27me3 signal hypermethylated phenotype, mainly occupying polycomb repressive complex 2 (PRC2) binding...